PANTHERx® Rare Pharmacy Selected by ChemoCentryx to Distribute TAVNEOS™ (avacopan) in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis
Read the Official PANTHERx Press Release. PANTHERx Rare Pharmacy announces that it has been selected by ChemoCentryx as a limited distribution partner for new drug TAVNEOS (avacopan). TAVNEOS, an orally administered selective complement 5a receptor inhibitor,...
Read More
PANTHERx® Rare Selected by Mitsubishi Tanabe Pharma America, Inc. (MTPA) as Exclusive Provider of U.S. Specialty Pharmacy Services for EXSERVAN™ (riluzole) oral film
Read the Official PANTHERx Press Release. PANTHERx Rare announced today that it was selected by Mitsubishi Tanabe Pharma America, Inc. (MTPA) as the exclusive U.S. pharmacy distribution partner for EXSERVAN™ (riluzole). The drug, an oral film formulation...
Read More
PANTHERx® Rare Pharmacy Selected by Rhythm Pharmaceuticals to Distribute IMCIVREE™ (setmelanotide) for Chronic Weight Management in Patients with Obesity Due to POMC, PCSK1 or LEPR Deficiency
Read the Official PANTHERx Press Release. PANTHERx® Rare Pharmacy announced today that it was selected by Rhythm Pharmaceuticals as the exclusive U.S. pharmacy distribution partner for IMCIVREE™ (setmelanotide). The drug was approved by the U.S. Food...
Read More
Centene Completes Acquisition of PANTHERx Rare Pharmacy (PANTHERx)
PANTHERx is proud to join the Centene family of companies. Through this transaction, we are reaffirming our relentless commitment to transforming lives and removing barriers for individuals living with complex and rare diseases. Read the official press...
Read More
Centene Signs Definitive Agreement to Acquire PANTHERx Rare Pharmacy (PANTHERx)
Today is a transformative day and the culmination of a great deal of effort and diligence to support the future of PANTHERx. We are very excited to announce that we have taken a significant step towards positioning ourselves for more sustainable growth...
Read More
PANTHERx Rare® Pharmacy Chosen as Partner by Alnylam Pharmaceuticals for OXLUMO™ (lumasiran) for the Treatment of Primary Hyperoxaluria Type 1 (PH1) to Lower Urinary Oxalate Levels
Read the Official PANTHERx Press Release. PANTHERx® Rare Pharmacy announces that it has been selected by Alnylam Pharmaceuticals, the leading RNAi therapeutics company, as a very limited distribution pharmacy partner for new drug OXLUMO™ (lumasiran)....
Read More